Introduction {#sec0005}
============

Tendons are a specialized type of tissue composed of tenoblasts and tenocytes, which are embedded in an extracellular matrix mostly composed of type I collagen. Tenocytes only have limited potential for proliferation and thus confer low regenerative capacity on tendons.[@bib0110], [@bib0115]

Tendon injuries constitute a serious problem within orthopedic practice and generate high costs for the public healthcare system, as well as having an impact on the quality of life of the patients affected. Although regeneration is the aim of the clinical treatments used, the methods currently available continue to be ineffective. Thus, tendon dysfunctions lead to definitive physical incapacity.[@bib0120], [@bib0125], [@bib0130]

Mesenchymal cells isolated from bone marrow stromal cells (BMSCs) are known to be a promising therapeutic option within the field of cell therapy and bioengineering of musculoskeletal tissues.[@bib0130], [@bib0135], [@bib0140], [@bib0145] Their use in association with synthetic biomaterials has been proposed as an option for modern treatments aiming to toward tendon reconstruction, using an allograft, autograft or xenograft.[@bib0150], [@bib0155] Use of autologous BMSCs biosynthetic grafts has the aims of improving the results from conservative surgery and reducing the time taken for the pre-injury biomechanical properties to be restored.[@bib0160] Furthermore, the low immunogenicity of BMSCs makes it possible to use them allogeneically and minimizes the need for immunosuppression of the receptor.[@bib0165]

Despite the significant therapeutic potential of BMSCs, little is yet known about the mechanisms and signaling pathways involved in determining that BMSCs will differentiate toward a tenogenic route, or in relation to progression of their differentiation. Considering that BMSCs seem to respond to stimuli that are present in extracts from healthy mature tissues and have specific phenotypic characteristics,[@bib0170], [@bib0175] we developed the hypothesis that tendon extracts might induce differentiation of BMSCs into tenocytes. Thus, the present study had the objective of evaluating the influence of treatment of human BMSCs with different concentrations of bovine tendon extract, on *in vitro* differentiation toward a tenocytic route.

Material and methods {#sec0010}
====================

Isolation and expansion of mesenchymal cells from the stroma of human bone marrow {#sec0015}
---------------------------------------------------------------------------------

BMSCs were isolated from surgical waste that originated from hip arthroplasty procedures on five patients (two men and three women) aged 45--60 years, who did not present any comorbidities. Informed consent was obtained from all of these individuals after approval of the study protocol by the institutional ethics committee. After the samples had been collected in the surgical center, they were stored in sterile flasks containing Iscove\'s modified Dulbecco\'s medium (IMDM; Sigma--Aldrich, St. Louis, MO, USA), supplemented with 20% bovine fetal serum (BFS; Gibco, Grand Island, NY, USA), at 4 °C for not more than 18 h. To isolate the total cellular fraction, the bone marrow was resuspended in phosphate-buffered saline (PBS) solution and was mechanically dissociated from any bone fragments. The cell suspensions thus obtained were collected in 50 mL tubes and were centrifuged at 836 × *g* and 4 °C for 5 min. The cells were then resuspended in 50 mL of IMDM supplemented with 20% BFS and were counted using a Neubauer chamber. Following this, 6 × 10^5^ mononuclear cells were distributed in culturing flasks of volume 75 cm^2^, in 10 mL of IMDM with 20% BFS, and were maintained at 37 °C under 5% CO~2.~ Three days later, the non-adherent fraction was removed by means of lavage with PBS and the culturing medium was changed. After a further 14 days, the cells were removed using a solution of 0.125% trypsin and 0.78 mM EDTA and were expanded.

Preparation of bovine tendon extract {#sec0020}
------------------------------------

Five bovine calcaneal tendons were obtained. They were macerated mechanically and then were ground up using an electric blender of power 20 W, in the proportions of 1 g of tissue to 2 mL of IMDM, without BFS.[@bib0180] The tissue extract was°C centrifuged at 836 × *g* and 8 °C for 5 min and was then stored at −80 °C for a maximum of two months.

Analysis of cell viability using the MTT method {#sec0025}
-----------------------------------------------

BMSCs were cultured on 24-well plates, at a density of 2.5 × 10^4^ cells/well and were treated with bovine tendon extract diluted in the proportions of 1:10, 1:50 or 1:250 (v/v) in IMDM supplemented with 10% BFS. Cell viability was assessed 24, 72, 120 and 168 hours after the treatment, in the presence of MTT (thiazolyl blue tetrazolium bromide; Sigma--Aldrich) at a concentration of 25 mg/mL. Equal concentrations of dimethyl sulfoxide (DMSO) were used as a negative control. Colorimetric evaluation was performed at a wavelength of 550 nm, using the SIRIO S SEAC reader (Burladingen, Germany).

Analysis of gene expression using qPCR {#sec0030}
--------------------------------------

BMSCs were cultured under the different experimental conditions described above (1:10, 1:50 or 1:250, v/v), for 7, 14 or 21 days. The cells were then washed and the total RNA was extracted using the Trizol^®^ method (Invitrogen Corp., Carlsbad, CA, USA) and was treated using DNase (Ambion^®^ DNA-free™ DNase treatment; Life Technologies), in accordance with the manufacturer\'s instructions. The integrity and quantity of the RNA were evaluated by means of electrophoresis on denaturing gel and by means of spectrophotometry (Nanodrop™ 1000; Thermo Fisher Scientific, Inc.). Reverse transcription for synthesis of complementary DNA (cDNA) was performed in duplicate, from 1.0 μg of RNA, using the ImProm-[II]{.smallcaps}™ reverse transcription system (Promega), in accordance with the manufacturer\'s protocol. qPCR was performed using the Power Sybr Green Master MIX^®^ detection system (Applied Biosystems, Molecular Probes, Inc.) in the Step One equipment (Applied Biosystems, Molecular Probes, Inc.). Primers from the constitutive genes (rDNA 28S and actin) were used as controls for the experiment. The expression of the genes for type I collagen, biglycan and fibromodulin was normalized in relation to the expression of the constitutive gene for β-actin ([Table 1](#tbl0005){ref-type="table"}). The 2^−ΔΔ*C*~*T*~^[@bib0170] method was used for analyzing the expression of the target genes of this study in relation to the constitutive gene. The values for relative expression that have been presented took the fixed control-group value of 1.0 as the reference (calibrator).

Results {#sec0035}
=======

With the aim of evaluating the toxicity of bovine tendon extract toward BMSCs, the MTT test was performed. The results showed that the bovine tendon extract did not alter the viability of the BMSCs at any of the concentrations tested ([Fig. 1](#fig0005){ref-type="fig"}). Thus, we can infer that the bovine tendon extract did not have any cytotoxic effect on the mesenchymal stem cells.

Given that there was no cytotoxic effect, the potential of the bovine tendon extract for differentiation was tested with the aim of evaluating whether the growth factors present in the extract would stimulate differentiation of the mesenchymal progenitor cells. We observed that in the BMSCs, the extract was capable of activating expression of the genes for type I collagen ([Fig. 2](#fig0010){ref-type="fig"}), biglycan ([Fig. 3](#fig0015){ref-type="fig"}) and fibromodulin ([Fig. 4](#fig0020){ref-type="fig"}) over periods of 7, 14 and 21 days. These results showed that the bovine tendon extract was not cytotoxic and that it was capable of inducing expression of the genes implicated in tenocytic differentiation of mesenchymal stem cells. Furthermore, the tendon protein extract promoted induction in a dose-dependent manner and as a function of the duration of exposure to the extract.

Discussion {#sec0040}
==========

Our study showed that the bovine tendon extract had the potential to induce tenocytic differentiation of BMSCs and that this extract did not have cytotoxicity at any of the concentrations used. In our analyses, the results showed that there was a spatial and temporal window for success regarding differentiation of BMSCs into tenocytes. We emphasize that for the procedure to be efficient, the BMSCs (at 70% confluence) should be treated with tendon extract at 1:50 for seven days. We observed that the peak expression of biglycan and fibromodulin (which are markers for tenocytes)[@bib0185], [@bib0190], [@bib0195], [@bib0200], [@bib0205], [@bib0210] was at this time. This indicated that the BMSCs became committed to a tenocytic lineage. The treatment protocol needs to proceed with increased concentration of the extract, which should be 1:10 for another 10 days. This allows the BMSCs to maintain type I collagen expression and provide an efficient extracellular matrix, so as also to maintain cell viability.

Our results suggest that in tendons, there are growth factors that stimulate differentiation of pluripotent cells into tendon cells. This opens up a possibility for the field of cell therapy, for treating tendinopathy. Finally, the potential was evaluated in an *in vitro* model and therefore there is a need for validation in an *in vivo* model, in order to confirm the results. Moreover, we raise the possibility that, in the future, the potential of tendon extracts originating from human tendons in cadaver donors might be evaluated.

Conclusions {#sec0045}
===========

The set of results showed that treatment of BMSCs with a protein extract from bovine tendon tissue promoted differentiation into tenocytes.
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![Evaluation of the cytotoxicity of bovine tendon extract in mesenchymal cells of the bone marrow stroma. C represents control condition; 1:10, 1:50 and 1:250 represent the dilutions of the bovine tendon extract in IMDM; B represents the control condition for the technique in which there were no cells. Under all conditions, IMDM was used with supplementation with 1% BFS.](gr1){#fig0005}

![Gene expression of type I collagen in mesenchymal cells of the bone marrow stroma, treated with increasing concentrations of bovine tendon extract (1:10, 1:50 and 1:250). Data normalized in relation to the expression of the constitutive gene ACTB.](gr2){#fig0010}

![Evaluation of biglycan expression through qPCR on mesenchymal stromal cells treated with increasing concentrations of bovine tendon extract (1:10, 1:50 and 1:250).](gr3){#fig0015}

![Evaluation of fibromodulin expression through qPCR on mesenchymal stromal cells treated with increasing concentrations of bovine tendon extract (1:10, 1:50 and 1:250).](gr4){#fig0020}

###### 

Target genes and designs of the primers used in analyzing gene expression.

  Target gene   Access number                                  Sequence (5′--3′)   Product (bp)            
  ------------- ---------------------------------------------- ------------------- ----------------------- -----
  COL1A1        [NM_000088.3](ncbi-n:NM_000088.3){#intr0005}   Sense               GTGCTCCTGGTATTGCTGGT    150
  Antisense     GCTCTCCCTTAGCACCAGTGT                                                                      
                                                                                                           
  BGN           [NM_001711.4](ncbi-n:NM_001711.4){#intr0010}   Sense               TGAAGTCTGTGCCCAAAGAGA   157
  Antisense     GCCTTCTCATGGATCTTGGA                                                                       
                                                                                                           
  FMOD          [NM_002023.4](ncbi-n:NM_002023.4){#intr0015}   Sense               CAACACCTTCAATTCCAGCA    178
  Antisense     CTGCAGCTTGGAGAAGTTCA                                                                       
                                                                                                           
  ACTB          [NM_001101.3](ncbi-n:NM_001101.3){#intr0020}   Sense               TACAATGAGCTGCGTGTGG     165
  Antisense     AGAGGCGTACAGGGATAGCA                                                                       

COL1A1, type 1A collagen; BGN, biglycan; FMOD, fibromodulin; ACTB, beta actin; bp, size of amplified product in base pairs.
